Part 10/Chapter 55/19-min read

Chronic Venous Disease, Varicose Veins, Venous Ulcers, and Superficial Interventions

Chronic venous disease as a population-health problem rather than a cosmetic niche: CEAP-classified disease driven by symptoms, skin change, and ulcer history. The chapter frames duplex evaluation, conservative management, superficial venous interventions, and venous ulcer care.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·5 sections · 24 references

Listen to this chapter7 min · AI audio edition · two hostsAI narration

Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.

Choose the hosts

Chronic venous disease classification and clinical assessment

Chronic venous disease is common enough that surgical trainees should treat it as a population-health problem, not a cosmetic niche. In the Edinburgh Vein Study, a general-population cohort of adults aged 18–64 years, truncal varicose veins were reported in 40% of men and 32% of women, and chronic venous insufficiency in 9% of men and 7% of women, with prevalence increasing sharply with age. The practical lesson is that symptoms, skin change, and ulcer history—not sex or age alone—should drive the seriousness of assessment.

TreatmentAge and frailty in chronic venous disease treatment
  • NICE CG168 (2013) recommends referral to a vascular service for symptomatic varicose veins, skin changes (eczema, hyperpigmentation), superficial vein thrombosis, or healed/active leg ulceration. Endothermal ablation is the first-line interventional treatment in NHS-funded patients with truncal reflux; foam sclerotherapy is second-line when ablation is unsuitable; surgery is third-line.
    Trigger
    NHS adults referred for symptomatic varicose veins.
    Branch / Endpoint
    NICE guidance is health-system specific and may diverge from US payer pathways.
    Citation
  • The Obermayer et al. 2017 US venous registry analysis evaluated outcomes of varicose vein procedures across age groups and reported that older adults (>70 years) achieved clinically meaningful improvement in QoL and symptom scores after endovenous ablation, comparable to younger patients, supporting that age alone should not exclude patients from intervention.
    Trigger
    Adults undergoing varicose vein procedures.
    Branch / Endpoint
    Frailty, comorbidity, and life-expectancy still inform individualized decision-making.
    Citation

Use standardized language from the first encounter. CEAP provides the reporting framework for chronic venous disease terminology, and VCSS is the standard severity instrument used across venous trials and cohorts. For a surgical consultation, the minimum useful assessment is not simply “varicose veins present”; it is a reproducible description of clinical class, symptom burden, skin findings, ulcer status, and baseline severity so that treatment response and recurrence can be judged later.

Referral is appropriate when varicose veins are symptomatic, when venous skin changes such as eczema or hyperpigmentation are present, when superficial vein thrombosis has occurred, or when there is healed or active leg ulceration. These referral triggers are useful because they separate uncomplicated visible varicosities from disease that may justify vascular-laboratory assessment and intervention.

Age should not be used as a stand-alone exclusion criterion for superficial venous intervention. A US venous registry analysis reported clinically meaningful symptom and quality-of-life improvement after endovenous ablation in adults older than 70 years, comparable to younger patients; the operative judgment is therefore to assess frailty, comorbidity, goals of care, mobility, wound burden, and life expectancy rather than to deny treatment solely because the patient is elderly.

Modern clinical assessment should also acknowledge that guideline frameworks now cover the continuum from C2 to C6 disease, including initial treatment selection, compression, pharmacologic adjuncts, tributary treatment, complications, and follow-up. The surgeon’s role is to translate those frameworks into a patient-specific plan: define the clinical problem, confirm anatomy, choose a treatment pathway, and document the outcome measure that will determine whether treatment succeeded.

Duplex mapping and reflux/obstruction decision points

Duplex mapping is the anatomic bridge between clinical classification and treatment selection. The operative plan should identify whether symptoms, skin change, or ulceration are associated with truncal reflux that is suitable for endovenous treatment, because treatment recommendations for symptomatic varicose veins and ulcer-associated reflux depend on confirming the venous target rather than treating visible tributaries alone.

TreatmentUlcer-with-superficial-reflux timing algorithm
  • The 2021 Cochrane review by Whing et al. (24 RCTs, 5,135 participants) found that endovenous ablation (laser and radiofrequency) and foam sclerotherapy achieved comparable technical success and quality-of-life improvement to conventional surgical stripping for great saphenous vein incompetence; radiofrequency ablation may offer a long-term advantage in reducing recurrence. Evidence certainty ranged from low to moderate due to methodological limitations.
    Trigger
    Patients with great saphenous vein incompetence undergoing varicose vein treatment (laser, radiofrequency, foam, surgery).
    Branch / Endpoint
    Evidence certainty is low to moderate; individual comparisons have limited trial numbers. Long-term recurrence data beyond 5 years are sparse.
    Citation
  • J Clin Med 2026 single-center retrospective cohort of EVLA outcomes specifically in patients with anterior accessory saphenous vein (AASV) insufficiency, reporting effectiveness and limitations of EVLA when the target vessel is anterior accessory rather than great or small saphenous trunk — directly addressing the accessory saphenous vein evidence gap documented as an evidence gap.
    Trigger
    When the incompetent target is the anterior accessory saphenous vein (AASV) rather than the great or small saphenous trunk.
    Branch / Endpoint
    —
    Citation
  • Use early endovenous ablation plus compression to accelerate venous-ulcer healing compared with deferred ablation when the patient fits EVRA criteria.
    Trigger
    Venous leg ulcer with superficial reflux and anatomy suitable for early endovenous ablation.
    Branch / Endpoint
    The EVRA primary trial supports timing of ablation; pair it with longer follow-up data when discussing recurrence and durability.
    Citation
  • The 3-year follow-up of the EVRA randomized trial (Gohel et al. 2020, JAMA Surgery, 450 participants) found that early endovenous ablation with compression reduced annual venous ulcer recurrence from 0.16 to 0.11 per person-year (34% reduction) versus deferred ablation, and was cost-effective at 91.6% probability at a £20,000/QALY threshold.
    Trigger
    Adults with venous leg ulcers of less than 6 months duration with superficial venous reflux (EVRA trial, 20 UK centers).
    Branch / Endpoint
    Results apply to patients with relatively short-standing ulcers; longer-duration ulcers may show different response to early ablation.
    Citation

For great saphenous incompetence, contemporary comparative evidence supports endovenous ablation, foam sclerotherapy, and conventional surgery as effective treatment families, with endovenous laser and radiofrequency ablation achieving technical success and quality-of-life improvement comparable to stripping in randomized trial syntheses. Because the certainty of evidence varies and long-term recurrence data are limited, duplex findings should be matched to patient priorities, local expertise, and the likelihood that a given modality will close the refluxing segment while preserving a practical recovery pathway.

A useful mapping report distinguishes the axial truncal problem from tributary disease and from less common target vessels. The guideline literature explicitly addresses treatment of varicose tributaries, while newer vessel-axis evidence includes outcomes for anterior accessory saphenous vein insufficiency treated with EVLA, reinforcing that non-great-saphenous reflux requires deliberate identification rather than being treated as an afterthought.

When selecting among modalities, the trainee should understand that “endovenous” is not a single technique. Thermal ablation, foam sclerotherapy, mechanochemical ablation, cyanoacrylate closure, surgery, and hemodynamic strategies such as CHIVA represent different treatment philosophies and risk profiles. The evidence base includes comparative trials and systematic reviews across these approaches, but the surgeon’s decision must remain anchored to the mapped reflux pattern and the patient’s clinical goal.

The decision point is not simply whether reflux is present, but whether the reflux explains the patient’s disease and whether intervention is expected to improve symptoms, skin change, ulcer healing, or recurrence risk. In venous ulcer patients, the EVRA evidence base supports early ablation timing when superficial reflux is present in patients with relatively short-standing ulcers, while older recurrence-prevention trials support the broader concept that superficial reflux correction has a role in ulcer recurrence context.

Compression, superficial intervention, and ulcer care

Compression is the foundation of venous leg ulcer care. Systematic review evidence supports compression over no compression for ulcer healing, and multilayer high-compression systems heal more ulcers than single-layer low-compression systems; four-layer bandages and short-stretch bandages have comparable healing rates. At the bedside, the most important technical issue is often not the brand of bandage but whether the patient can tolerate, apply, and continue the system while skin care and wound care are maintained.

A later Cochrane synthesis focusing specifically on compression versus no compression across 14 randomized trials reported moderate-certainty evidence that compression accelerates venous ulcer healing. This is a useful teaching point for surgical trainees: before escalating to procedural therapy, document whether compression has been prescribed, whether it is actually being worn, and what barrier—pain, exudate, dermatitis, mobility, application difficulty, or preference—is preventing adherence.

After healing, compression remains a recurrence-prevention intervention, but the best prescription is the one the patient will use. A 2024 Cochrane review found that higher-compression hosiery was more effective than lower-compression or no compression for preventing recurrence, while class 2 compression was better tolerated than class 3. Therefore, a patient who cannot adhere to higher compression may be better served by a lower class worn consistently than by a theoretically stronger stocking left in a drawer.

Superficial intervention is first-line in selected patients with truncal reflux when the anatomy and clinical indication align. NICE places endothermal ablation first for truncal reflux, foam sclerotherapy second when ablation is unsuitable, and surgery third; randomized evidence indicates that endovenous laser, radiofrequency ablation, and foam can provide technical success and quality-of-life improvement comparable to conventional stripping for great saphenous incompetence, with low-to-moderate certainty and limited long-term recurrence data.

In active venous ulceration with superficial reflux, timing matters. The 3-year EVRA follow-up showed that early endovenous ablation plus compression reduced annual ulcer recurrence from 0.16 to 0.11 per person-year compared with deferred ablation and was cost-effective at the cited UK threshold; the caveat is that the trial population had ulcers of less than 6 months’ duration, so trainees should avoid assuming identical benefit in long-standing, complex, or poorly characterized ulcers.

Guideline comparison

Carroll Compression Cochrane · 2014

  1. The 2014 Cochrane review by O'Meara et al. (referenced as Carroll in metadata) on compression for venous leg ulcers concluded that compression healing is superior to no compression, that multi-layer high-compression systems heal more ulcers than single-layer low-compression systems, and that four-layer bandages and short-stretch bandages are comparable in healing rates.
    Applies to
    Adults with venous leg ulcer requiring compression.
    Boundary
    Patient adherence is the dominant determinant of compression success; consider stretch, comfort, and skin care.
Cochrane Review Compression Versus No Compression For Venous Leg Ulcer Healing Shi And Dumville · 2021
  1. Cochrane Database 2021 systematic review by Shi and Dumville evaluates the specific 'compression vs no compression' question for venous leg ulcer healing across 14 RCTs (1,391 participants), providing moderate-certainty evidence that compression accelerates healing.
    Applies to
    Patients with venous leg ulcers, comparing compression therapy with no compression for ulcer healing (14 RCTs, 1,391 participants).
    Boundary
    Based on moderate-certainty evidence comparing compression with no compression for ulcer healing; findings apply to venous leg ulcer patients.
Silva Cochrane Compression Recurrence · 2024
  1. The 2024 Cochrane review by Silva et al. (8 RCTs, 1,995 participants) on compression for preventing venous ulcer recurrence found that higher-compression hosiery (European class 3 or UK class 3) was more effective than lower-compression or no compression; however, class 2 compression was better tolerated, making adherence a key clinical consideration when selecting compression class for long-term ulcer recurrence prevention.
    Applies to
    Adults with healed venous ulcers requiring long-term compression for recurrence prevention.
    Boundary
    Class 3 compression may reduce recurrence more than class 2 but adherence is lower; the optimal compression class depends on patient preference, skin condition, and mobility.
Gohel Evra 3yr Jamasurg · 2020
  1. The 3-year follow-up of the EVRA randomized trial (Gohel et al. 2020, JAMA Surgery, 450 participants) found that early endovenous ablation with compression reduced annual venous ulcer recurrence from 0.16 to 0.11 per person-year (34% reduction) versus deferred ablation, and was cost-effective at 91.6% probability at a £20,000/QALY threshold.
    Applies to
    Adults with venous leg ulcers of less than 6 months duration with superficial venous reflux (EVRA trial, 20 UK centers).
    Boundary
    Results apply to patients with relatively short-standing ulcers; longer-duration ulcers may show different response to early ablation.
Paravastu Pentoxifylline Cochrane · 2016
  1. The 2016 Cochrane review by Paravastu et al. on pentoxifylline (400 mg three times daily) for venous leg ulcers concluded that pentoxifylline plus compression is more effective than compression alone in promoting complete ulcer healing (RR 1.70, 95% CI 1.30-2.24), and that pentoxifylline without compression is more effective than placebo. The review includes 12 trials and 864 participants.
    Applies to
    Adults with venous leg ulcer with or without compression.
    Boundary
    Common adverse effects include gastrointestinal upset (nausea, dyspepsia); titration may improve tolerance.
Cochrane Review Sulodexide For Venous Leg Ulcer Healing Wu And Colleagues · 2016
  1. Cochrane Database 2016 systematic review by Wu and colleagues evaluates sulodexide (oral glycosaminoglycan) for venous leg ulcer healing across four RCTs (463 participants), providing a drug-class-specific pharmacotherapy synthesis distinct from pentoxifylline.
    Applies to
    Patients with venous leg ulcers treated with sulodexide (oral glycosaminoglycan) as adjunctive pharmacotherapy (4 RCTs, 463 participants).
    Boundary
    Findings apply to venous leg ulcer patients receiving sulodexide as adjunctive pharmacotherapy and may not generalise to other settings.
Source · · · · ·

Adjunctive pharmacotherapy may be considered in selected venous ulcer patients, but it should not distract from compression and reflux management. Pentoxifylline 400 mg three times daily improved complete healing when added to compression and also outperformed placebo without compression in a 12-trial Cochrane review, with gastrointestinal upset as a common limitation; sulodexide has also been evaluated in a separate Cochrane review across four randomized trials, providing a distinct drug-class evidence base rather than a substitute for mechanical and anatomic treatment.

Deep venous, perforator, and pelvic/splanchnic boundaries

This chapter’s intervention focus is superficial venous disease, so the trainee must recognize the boundary between an appropriate superficial procedure and a venous presentation that requires broader evaluation. Current society guidance addresses assessment and treatment of chronic venous disease, including initial treatment selection across C2–C6 presentations, but the operative plan should not treat superficial reflux as the only possible explanation for every swollen, pigmented, or ulcerated limb.

Guideline comparison

Demaeseneer ESVS CVD · 2022

  1. ESVS 2022 chronic venous disease guideline provides graded clinical practice recommendations for assessment and treatment of chronic venous disease.
    Applies to
    Patients with chronic venous disease across C2-C6 severity, including varicose veins, venous skin change, healed ulceration, or active venous leg ulceration.
    Boundary
    Guideline recommendation; consult the source guideline for the exact class and level-of-evidence wording.
Gloviczki SVS AVF Avls Part1 · 2023
  1. Companion document to Part II; addresses C2-C6 evaluation and initial treatment selection
    Applies to
    Patients with symptomatic lower-extremity varicose veins or chronic venous disease undergoing evaluation and initial treatment selection.
Gloviczki SVS AVF Avls Part2 · 2024
  1. The 2023 SVS/AVF/AVLS Part II guideline (Gloviczki et al., 2024) addresses compression, drug therapy, treatment of varicose tributaries, superficial venous aneurysms, and management of treatment complications, using GRADE methodology and an independent systematic review. Recommendations cover post-procedural compression duration, micronized purified flavonoid fraction for symptomatic CVD, ambulatory phlebectomy and foam for tributary varicosities, and management of endothermal heat-induced thrombosis (EHIT).
    Applies to
    Adults undergoing or recovering from intervention for lower-extremity varicose veins.
    Boundary
    Individual recommendations carry differing strength and evidence grades under the GRADE framework.
Gohel Evra 3yr Jamasurg · 2020
  1. The 3-year follow-up of the EVRA randomized trial (Gohel et al. 2020, JAMA Surgery, 450 participants) found that early endovenous ablation with compression reduced annual venous ulcer recurrence from 0.16 to 0.11 per person-year (34% reduction) versus deferred ablation, and was cost-effective at 91.6% probability at a £20,000/QALY threshold.
    Applies to
    Adults with venous leg ulcers of less than 6 months duration with superficial venous reflux (EVRA trial, 20 UK centers).
    Boundary
    Results apply to patients with relatively short-standing ulcers; longer-duration ulcers may show different response to early ablation.
Source · · ·

Perforator and tributary findings should be interpreted in the context of the whole limb rather than used as isolated procedural targets. SVS/AVF/AVLS Part II specifically includes treatment of varicose tributaries and post-procedural issues, supporting a structured approach in which truncal, tributary, and complication management are part of one plan rather than disconnected procedures.

Deep venous disease and pelvic or splanchnic venous problems fall at the edge of superficial-intervention decision-making. The practical boundary is that superficial ablation is most defensible when the mapped reflux target is clinically concordant; when clinical severity, swelling, ulcer behavior, or recurrence appears disproportionate to the superficial findings, the surgeon should pause and reassess whether the patient’s disease is being explained adequately by the superficial map alone.

Pelvic-source and accessory-source reflux are examples of why mapping discipline matters. Although the chapter’s strongest comparative evidence centers on great saphenous incompetence, emerging target-specific evidence for anterior accessory saphenous vein insufficiency highlights the need to identify the actual reflux pathway before selecting EVLA, RFA, foam, surgery, MOCA, cyanoacrylate closure, or another approach.

The safest operative habit is to state the boundary explicitly in the note: what the superficial procedure is intended to treat, what it is not intended to treat, and what clinical outcome will trigger reassessment. This is particularly important in ulcer patients, where compression, early superficial ablation in suitable patients, and recurrence prevention are evidence-supported, but persistent or recurrent ulceration should prompt reconsideration of anatomy, adherence, and competing venous mechanisms.

Follow-up, recurrence, and patient-centered outcomes

Follow-up after superficial venous intervention should measure the patient’s outcome, not merely record that a procedure occurred. VCSS provides a standard severity instrument across venous studies, and contemporary guideline documents address treatment complications and recovery after intervention; together they support structured documentation of symptoms, skin status, ulcer status, compression use, and complications.

The post-procedural visit should actively look for treatment failure modes: persistent symptoms despite closure, recurrent varicosities, poor compression adherence, ulcer recurrence, tributary disease that was not addressed, and procedure-related thrombosis. The EHIT consensus terminology provides a management reference point after superficial ablation, and SVS/AVF/AVLS guidance includes management of endothermal heat-induced thrombosis among treatment complications.

Guideline comparison

VCSS-based outcome tracking form

Vasquez Vcss · 2010
  1. Standard outcomes severity instrument used across venous trials and cohorts
    Applies to
    Patients with chronic venous disease whose symptoms, skin findings, ulcer status, and treatment response require standardized VCSS tracking.
Gloviczki Ehit AVF SVS · 2021
  1. Canonical EHIT terminology and management reference point after superficial ablation
    Applies to
    Patients undergoing superficial venous ablation who require EHIT terminology, surveillance, or management decisions.
EHIT Consensus Guidance · 2021
  1. Open-access EHIT consensus adds complication-management source diversity for superficial venous intervention.
    Applies to
    Open-access EHIT consensus adds complication-management source diversity for superficial venous intervention.
Silva Cochrane Compression Recurrence · 2024
  1. The 2024 Cochrane review by Silva et al. (8 RCTs, 1,995 participants) on compression for preventing venous ulcer recurrence found that higher-compression hosiery (European class 3 or UK class 3) was more effective than lower-compression or no compression; however, class 2 compression was better tolerated, making adherence a key clinical consideration when selecting compression class for long-term ulcer recurrence prevention.
    Applies to
    Adults with healed venous ulcers requiring long-term compression for recurrence prevention.
    Boundary
    Class 3 compression may reduce recurrence more than class 2 but adherence is lower; the optimal compression class depends on patient preference, skin condition, and mobility.
Source · · ·

Recurrence prevention in venous ulcer disease is longitudinal care. Higher-compression hosiery reduces recurrence more than lower-compression or no compression, but lower compression is often better tolerated; therefore, follow-up should include a frank adherence discussion and adjustment of compression class to the patient’s skin condition, mobility, and preferences.

Durability expectations should be honest. Randomized and cohort evidence supports multiple modalities—thermal ablation, foam, surgery, mechanochemical ablation, cyanoacrylate closure, and hemodynamic approaches—but the certainty and follow-up depth differ across comparisons. Patients should understand that early symptom improvement and long-term freedom from recurrence are related but not identical outcomes.

Patient-centered selection also means avoiding therapeutic nihilism. Older adults in registry data experienced meaningful symptom and quality-of-life improvement after endovenous ablation, so the follow-up plan for an elderly patient should be as deliberate as for a younger patient: define the expected benefit, check whether it occurred, and reassess when symptoms, ulcer behavior, or recurrence do not match the original anatomic explanation.

References

  1. 1.
    ESCHAR trial: surgery plus compression versus compression alone in chronic venous ulceration DOI: 10.1016/S0140-6736(04)16091-0
    PubMed-indexed articleRandomized controlled trial2004
    PubMedDOI
  2. 2.
    Classification and treatment of endothermal heat-induced thrombosis: recommendations from the American Venous Forum and Society for Vascular Surgery PMID: 33012690
    PubMed-indexed articleClinical practice guideline2021
    PubMedOpen PDF
  3. 3.
    Early endovenous ablation in venous ulceration (EVRA original trial) DOI: 10.1056/NEJMoa1801214
    PubMed-indexed articleRandomized controlled trial2018
    PubMedDOI
  4. 4.
    CHIVA method for the treatment of chronic venous insufficiency DOI: 10.1002/14651858.CD009648.pub4
    PubMed-indexed articleMeta-analysis / systematic review2021
    PubMedDOIOpen PDF
  5. 5.
    Compression bandages or stockings versus no compression for treating venous leg ulcers DOI: 10.1002/14651858.CD013397.pub2
    PubMed-indexed articleMeta-analysis / systematic review2021
    PubMedDOIOpen PDF
  6. 6.
    Sulodexide for treating venous leg ulcers DOI: 10.1002/14651858.CD010694.pub2
    PubMed-indexed articleMeta-analysis / systematic review2016
    PubMedDOIOpen PDF
  7. 7.
    Three-year outcomes after cyanoacrylate closure of superficial truncal veins: A single-center practice cohort study. PMID: 41780674
    PubMed-indexed articleRegistry / cohort2026
    PubMedOpen PDF
  8. 8.
    Effectiveness and Limitations of Endovenous Laser Ablation for Anterior Saphenous Vein Insufficiency: A Single-Center Retrospective Study. PMID: 41827148
    PubMed-indexed articleRegistry / cohort2026
    PubMedOpen PDF
  9. 9.
    Compression for venous leg ulcers. 2012.
    PubMed-indexed articleMeta-analysis / systematic review2012

    Compression for venous leg ulcers. 2012. doi:10.1002/14651858.cd000265.pub3.

    PubMedDOI
  10. 10.
    The 2020 update of the CEAP classification system and reporting standards. 2020.
    PubMed-indexed article2020

    The 2020 update of the CEAP classification system and reporting standards. 2020. doi:10.1016/j.jvsv.2019.12.075. PMID:32113854.

    PubMedDOI
  11. 11.
    Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. 1999.
    PubMed-indexed articleRegistry / cohort1999

    Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. 1999. doi:10.1136/jech.53.3.149.

    PubMedDOI
  12. 12.
    The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. 2024.
    PubMed-indexed articleClinical practice guideline2023

    The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. 2024. doi:10.1016/j.jvsv.2023.08.011. PMID:37652254.

    PubMedDOI
  13. 13.
    The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology. 2023.
    PubMed-indexed articleClinical practice guideline2022

    The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology. 2023. doi:10.1016/j.jvsv.2022.09.004. PMID:36326210.

    PubMedDOI
  14. 14.
    Long-term Clinical and Cost-effectiveness of Early Endovenous Ablation in Venous Ulceration: A Randomized Clinical Trial (2020) DOI: 10.1001/jamasurg.2020.3845
    PubMed-indexed articleRandomized controlled trial2020
    PubMedDOIOpen PDF
  15. 15.
    Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. 2020.
    PubMed-indexed articleRandomized controlled trial2020

    Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial. 2020. doi:10.1016/j.jvsv.2019.10.025. PMID:31864932.

    PubMedDOI
  16. 16.
    Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. 2020.
    PubMed-indexed articleRandomized controlled trial2020

    Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. 2020. doi:10.1016/j.jvsv.2019.12.080. PMID:32205125.

    PubMedDOI
  17. 17.
    Diagnosis and management of varicose veins in the legs: summary of NICE guidance. 2013.
    PubMed-indexed articleClinical practice guideline2013

    Diagnosis and management of varicose veins in the legs: summary of NICE guidance. 2013. doi:10.1136/bmj.f4279.

    PubMedDOI
  18. 18.
    Pentoxifylline for treating venous leg ulcers. 2012.
    PubMed-indexed articleMeta-analysis / systematic review2012

    Pentoxifylline for treating venous leg ulcers. 2012. doi:10.1002/14651858.cd001733.pub3.

    PubMedDOI
  19. 19.
    Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. 2011.
    PubMed-indexed articleRandomized controlled trial2011

    Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. 2011. doi:10.1002/bjs.7555. PMID:21725957.

    PubMedDOI
  20. 20.
    Compression for preventing recurrence of venous ulcers (2024) DOI: 10.1002/14651858.CD002303.pub4
    PubMed-indexed articleMeta-analysis / systematic review2024
    PubMedDOIOpen PDF
  21. 21.
    Age is not a barrier to good outcomes after varicose vein procedures.
    PubMed-indexed articleRegistry / cohort2017
    PubMedDOIOpen PDF
  22. 22.
    Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. 2010.
    PubMed-indexed articleClinical practice guideline2010

    Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. 2010. doi:10.1016/j.jvs.2010.06.161. PMID:20875713.

    PubMedDOI
  23. 23.
    Interventions for great saphenous vein incompetence (2021) DOI: 10.1002/14651858.CD005624.pub4
    PubMed-indexed articleMeta-analysis / systematic review2021
    PubMedDOIOpen PDF
  24. 24.
    ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs DOI: 10.1016/j.ejvs.2021.12.024
    PubMed-indexed articleClinical practice guideline2022
    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions